Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Heart failure associated with imported malaria: a nationwide Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversies

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sex differences in congestive markers in patients hospitalized for acute heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Proteomic exploration of common pathophysiological pathways in diabetes and cardiovascular disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Brain tumours in children and adolescents may affect the circadian rhythm and quality of life

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Alexithymia, Emotional Distress, and Perceived Quality of Life in Patients With Hashimoto's Thyroiditis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Christoph Wanner
  • Ulla Feldt-Rasmussen
  • Ana Jovanovic
  • Aleš Linhart
  • Meng Yang
  • Elvira Ponce
  • Eva Brand
  • Dominique P Germain
  • Derralynn A Hughes
  • John L Jefferies
  • Ana Maria Martins
  • Albina Nowak
  • Bojan Vujkovac
  • Frank Weidemann
  • Michael L West
  • Alberto Ortiz
View graph of relations

Aims: Long-term treatment effect studies in large female Fabry patient groups are challenging to design because of phenotype heterogeneity and lack of appropriate comparison groups, and have not been reported. We compared long-term cardiomyopathy and kidney function outcomes after agalsidase beta treatment with preceding treatment-naive outcomes. Methods and results: Self-controlled pretreatment and post-treatment comparison (piecewise mixed linear modelling) included Fabry female patients ≥18 years at treatment initiation who received agalsidase beta (0.9–1.1 mg/kg every other week) for ≥2 years, with ≥2 pretreatment and ≥2 post-treatment outcome measurements during 10-year follow-up. Left ventricular posterior wall thickness (LVPWT)/interventricular septal thickness (IVST) and estimated glomerular filtration rate (eGFR, Chronic Kidney Disease Epidemiology Collaboration creatinine equation) analyses included 42 and 86 patients, respectively, aged 50.0 and 46.3 years at treatment initiation, respectively. LVPWT and IVST increased pretreatment (follow-up 3.5 years) but stabilized during 3.6 years of treatment (LVPWT: n = 38, slope difference [95% confidence interval (CI)] = −0.41 [−0.68, −0.15] mm/year, P pre–post difference <0.01; IVST: n = 38, slope difference = −0.32 [−0.67, 0.02] mm/year, P pre–post difference = 0.07). These findings were not modified by renal involvement or antiproteinuric agent use. Compared with the treatment-naive period (follow-up 3.6 years), eGFR decline remained modest and stabilized within normal ranges during 4.1 years of treatment (slope difference, 95% CI: −0.13 [−1.15, 0.89] mL/min/1.73m 2/year, P pre–post difference = 0.80). Conclusions: Cardiac hypertrophy, progressing during pretreatment follow-up, appeared to stabilize during sustained agalsidase beta treatment. eGFR decline remained within normal ranges. This suggests that treatment may prevent further Fabry-related progression of cardiomyopathy in female patients and maintain normal kidney function.

Original languageEnglish
JournalESC Heart Failure
Volume7
Issue number3
Pages (from-to)825-834
Number of pages10
ISSN2055-5822
DOIs
Publication statusPublished - 1 Jun 2020

    Research areas

  • Agalsidase beta, Cardiomyopathy, Enzyme replacement therapy, Fabry disease, Female patients, Kidney function

ID: 59977866